While in vivo investigation of the potential plasticity of our explant cultures is warranted, these findings together with our observations following mechanical, pharmacological or genetic modulation of the YAP1-TGFβ1 axis as well as trajectory analyses and lineage tracing studies [10, 17, 52, 68] strongly infer in vivo fibroblast plasticity during PCa progression and therapeutic challenge. The gene discussed is TGFB1; the disease is posterior cortical atrophy.